• Title/Summary/Keyword: 비소세포 폐암

Search Result 389, Processing Time 0.028 seconds

Gefitinib-Related Interstitial Pneumonia (Gefitinib 투여 후 발생한 간질성 폐렴)

  • Lee, Ho Jin;Nam, Seung Bum;Jung, Jae Wook;Na, Im Il;Kim, Cheol Hyeon;Ryoo, Baek-Yeol;Choe, Du Whan;Kang, Jin Hyung;Lee, Jae Cheol
    • Tuberculosis and Respiratory Diseases
    • /
    • v.62 no.2
    • /
    • pp.134-139
    • /
    • 2007
  • Gefitinib is a novel drug used to treat advanced non-small cell lung cancer. However, drug-related interstitial pneumonia is a major life-threatening side effect, which has a worldwide prevalence of 0.3-0.4%. In Japan, the prevalence is high as 3-4% but the actual frequency in Korea has not been officially assessed. We report two cases of gefitinib-induced interstitial lung disease during the treatment of non-small cell lung cancer. High-resolution computerized tomography (HRCT) of one case showed nonspecific ground glass opacity and the chest x-ray of another case showed diffuse bilateral ground glass opacity. The former patient showed a rapid good response to corticosteroid treatment whereas the latter died despite receiving aggressive treatment with high dose corticosteroid and empirical antibiotics.

Effects of the Combination Chemotherapy of Docetaxel and Cisplatin in Non-Small Cell Lung Cancer Patients (비소세포성 폐암환자에서의 Docetaxel과 Cisplatin의 복합요법에 대한 효과)

  • Bang, Eun Sook;Oh, Jung Mi
    • Korean Journal of Clinical Pharmacy
    • /
    • v.12 no.1
    • /
    • pp.1-6
    • /
    • 2002
  • Central Cancer Registry of Korean National Cancer Center in 1999 reported that mortality from lung cancer is higher than mortality from stomach cancer or hepatocellular carcinoma in Korean male. Lung cancer is classified into small cell cancer and non-small cell lung cancer (NSCLC), and NSCLC patients account for $70\%$ of the whole lung cancer patients. The purpose of this study was to evaluate the efficacy and toxicity of docetaxel and cisplatin combination in Korean patients with NSCLC. All patients who had received the combination therapy of docetaxel and cisplatin for histologically confirmed NSCLC in Ajou University Hospital between 2000. $2\~2001$. 4 were retrospectively evaluated for the responses and toxicities of that combination therapy. Nineteen patients were treated with docetaxel 75 $mg/m^2$ on Day 1 and cisplatin 25 $mg/m^2$ on Day 1-3 every 4 weeks. The response for combination regimen was evaluated by CT scans after 2 or 3 cycles of treatments. Seventeen patients were evaluated for the responses and the 19 patients far the toxicities. Among the 19 patients (14 men and 5 women), there were one patient $(5.3\%)$ with stage I disease, 4 patients $(21.1\%)$ with stage III disease, and 14 patients $(73.1\%)$ with stage IV disease. Of the 17 patients who were evaluable for response, complete response (CR) was not observed in any patient while partial response (PR) was observed in 5 patients $(29.4\%)$. The overall response rate (CR+PR) was $29.4\%$. Stable disease (SD) was observed in 11 patients $(64.7\%)$ and progressive disease (PD) in 1 patient $(5.9\%)$. The toxicities were graded by NCI (National Cancer Institute) Common Toxicity Criteria for the evaluable 70 cycles. Grade 3 or 4 neutropenia occurred in 53 cycles $(76\%)$. Four patients were hospitalized due to febrile neutropenia. The combination chemotherapy of docetaxel and cisplatin was effective as NSCLC treatments, however, the regimen must be administered carefully due to its hematological side effects.

  • PDF

A Case Report of Advanced Non-Small Cell Lung Cancer Patient Treated with Samchilchoongcho-Jung in Conjunction with Alectinib (알렉티닙과 삼칠충초정을 병용하여 호전된 진행성 비소세포성 폐암환자 1례)

  • Ko, Myung-hyun;Myong, Ji-soo;Park, So-jung;Jeon, Hyung-joon;Lee, Yeon-weol;Cho, Chong-kwan;Yoo, Hwa-seung
    • Journal of Korean Traditional Oncology
    • /
    • v.24 no.1
    • /
    • pp.1-9
    • /
    • 2019
  • Objective: The purpose of this study is to report the clinical effectiveness of advanced non-small cell lung cancer (NSCLC) with Samchilchoongcho-Jung (HAD-B1) in conjunction with Alectinib. Methods: The patient was diagnosed with Anaplastic lymphoma kinase (ALK) mutated (2+) non-small cell lung cancer adenocarcinoma stage IV, suffering from edema of lower extremities, dyspnea, pleural effusion, general weakness, insomnia. The patient being treated with Alectinib was treated with Samchilchoongcho-Jung (HAD-B1) for disease control and symptom management. The clinical outcomes were measured by National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE), Numeral rating scale (NRS) and Eastern Cooperative Oncology Group (ECOG). Results: After treatment, dyspnea and edema of lower extremities was relieved from NRS 7 to 5, and 6 to 1 respectively. And ECOG score of the patient was improved from grade 3 to 2. During and after treatment, we didn't find any severe toxicities on laboratory findings. Conclusion: This case study suggests that Samchilchoongcho-Jung (HAD-B1) may improve symptom relief and life quality of NSCLC patient in conjunction with Alectinib.

A Case of End-stage non-small cell Lung Cancer Patient with Brain Metastasis Treated with Pembrolizumab with Integrative Medicine Therapy (Pembrolizumab과 통합의학치료로 호전된 뇌전이 동반 말기 비소세포성 폐암 환자 1례)

  • Seo, Han Gil;Jin, Yong Jae;Song, Mi Hwa;Kim, In Tae;Park, Ji Hye;Jung, Jun Suk;Cho, Sung Kyoo;Shin, Kwang Soon
    • Journal of Korean Traditional Oncology
    • /
    • v.23 no.2
    • /
    • pp.11-25
    • /
    • 2018
  • Objective: The purpose of this study is to report the case of a patient with non-small cell lung cancer (NSCLC) with Programmed cell death protein 1 (PD-1) mutation treated by Integrative Medicine Therapy (IMT). Methods: A patient with metastatic NSCLC received pembrolizumab 200mg intravenously for every 3 weeks from July 2017. Repeat cycle every 3 weeks since July 2017. The patient has been treated with Integrative Medicine Therapy (IMT) since December 2016. The tumor size was measured by computed tomography (CT) and magnetic resonance imaging(MRI). Adverse events were evaluated by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0. Results: After combined treatment, the extent of proximal portion of primary tumor in the left lower lobe was decreased and disease status was stable radiologically. No evidence of newly developed metastatic lesions in the brain since May 2017. The patient did not experience any adverse event according to NCI-CTCAE ver. 5.0. Conclusion: This case study suggests that Integrative Medicine Therapy (IMT) may contribute to tumor response, in conjunction with Pembrolizumab on the treatment of patients with NSCLC.

A Case of Persistent Hiccups of Non-Small Cell Lung Cancer Patient Treated with Korean Medicine (한방 치료로 지속성 딸꾹질이 호전된 비소세포폐암 환자 치험 1례)

  • Ye-Chae, Hwang;Hye-Jin, Lee;Hye-Min, Heo;Gyu-Ri, Jeon;Seung-Yeon, Cho;Seong-Uk, Park;Jung-Mi, Park;Chang-Nam, Ko
    • The Journal of the Society of Stroke on Korean Medicine
    • /
    • v.23 no.1
    • /
    • pp.1-12
    • /
    • 2022
  • Persistent hiccups persist for more than 48 hours. Those can often occur in cancer patients after chemotherapy or high dose of corticosteroids. A 52-year-old male patient undergoing Non-small cell lung cancer(NSCLC), recently suffered presistent hiccups and dyspnea. He was treated with herbal medicine for 56days and acupuncture for 9days. No side effects were observed during treatment. The severity of hiccups was measured in every hospital visit and psychometric symptoms were evaluated periodically through the Edmonton Symptom Assessment System(ESAS). The severity of hiccups and psychometric symptoms were alleviated and the effect persisted during the treatment. The patient took no other nervous system drugs in the end of the treatment. In conclusion, Korean medicine like Hyeongbangjihwang-tang and Jeongcheonhwadamgangki-tang can be effective for patients with persistent hiccups and dyspnea who cannot use alternative drugs or treatment because of other complications.

Rapidly Destructive Arthrosis of Knee Following Treatment of Crizotinib in a Patient with Non-Small-Cell Lung Cancer (비소세포폐암 환자에서 크리조티닙 치료 후 발생한 급속 파괴형 슬관절증)

  • Hwang, Jin Tae;Choi, Jae-Hyeong;Park, Chul-Hyun;Yoon, Kyung Jae;Lee, Yong-Taek;Do, Jong Geol
    • Clinical Pain
    • /
    • v.19 no.2
    • /
    • pp.120-123
    • /
    • 2020
  • Rapidly destructive arthrosis is a rare syndrome characterized by narrowing of the joint space and rapid joint destruction within 6~12 months. A 62-year-old woman with anaplastic lymphoma kinase rearranged non-small-cell lung cancer presented with both knee pain and varus deformity. She was treated with crizotinib 500 mg/day for more than 2 years, with partial tumor response. Initial plain radiography showed Kellgren and Lawrence (K-L) grade 1. After 10 months, varus deformity was worsened and plain radiography aggravated to K-L grade 4 despite conservative treatment including activity modification. Diffuse synovitis with massive joint effusion and destruction of anterior cruciate ligament, medial meniscus, medial collateral ligament, and lateral collateral ligament were shown in magnetic resonance imaging. The patient was diagnosed with rapidly destructive arthrosis of knee and underwent a both total knee arthroplasty.

A Case Report of Recurrent L858R Mutation Non-Small-Cell Lung Cancer with Brain Metastases Treated with Erlotinib and Traditional Korean Medicine After Failure with Gefitinib (Gefitinib 내성 후 Erlotinb과 한방 치료를 병행하여 호전된 뇌전이를 동반한 재발성 L858R 변이 비소세포폐암 환자 1례)

  • Yang, Jung-min;Jang, Kwon-jun;Hwang, Woo-seok
    • The Journal of Internal Korean Medicine
    • /
    • v.43 no.5
    • /
    • pp.838-853
    • /
    • 2022
  • Objectives: The purpose of this study is to report the case of a patient with recurrent L858R mutation non-small-cell lung cancer with brain metastases treated with erlotinib and traditional Korean medicine after gefitinib failure. Methods: The patient was treated with erlotinib beginning in November 2021, and gamma knife surgery was performed on November 8, 2021. The dose of erlotinib was 150 mg/day every four weeks. At the same time, the patient was treated with traditional Korean medicine. Tumor size and cerebral edema were measured using computed tomography and magnetic resonance imaging, respectively. Adverse events were evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. Results: After treatment with erlotinib and traditional Korean medicine for six months, the extent of the growing nodule in the right upper lobe decreased during the first three months and remained stable for the following three months. Peritumoral edema showed an increase three months after gamma knife surgery, but partial improvement of cerebral edema was confirmed with additional traditional Korean medicine six months after gamma knife surgery. The symptoms of discomfort and physical activity gradually improved. Conclusions: This case study suggests that the combination of EGFR-TKI and traditional Korean medicine may contribute to a reduction in tumor size and cerebral edema while improving quality of life.

Assessment and Analysis of Fidelity and Diversity for GAN-based Medical Image Generative Model (GAN 기반 의료영상 생성 모델에 대한 품질 및 다양성 평가 및 분석)

  • Jang, Yoojin;Yoo, Jaejun;Hong, Helen
    • Journal of the Korea Computer Graphics Society
    • /
    • v.28 no.2
    • /
    • pp.11-19
    • /
    • 2022
  • Recently, various researches on medical image generation have been suggested, and it becomes crucial to accurately evaluate the quality and diversity of the generated medical images. For this purpose, the expert's visual turing test, feature distribution visualization, and quantitative evaluation through IS and FID are evaluated. However, there are few methods for quantitatively evaluating medical images in terms of fidelity and diversity. In this paper, images are generated by learning a chest CT dataset of non-small cell lung cancer patients through DCGAN and PGGAN generative models, and the performance of the two generative models are evaluated in terms of fidelity and diversity. The performance is quantitatively evaluated through IS and FID, which are one-dimensional score-based evaluation methods, and Precision and Recall, Improved Precision and Recall, which are two-dimensional score-based evaluation methods, and the characteristics and limitations of each evaluation method are also analyzed in medical imaging.

A Case Report on the Improvement of Cancer Pain in a Patient with Metastatic Non-Small Cell Lung Cancer Through Herbal Medicine-based Integrative Cancer Treatment with Chemotherapy (항암화학요법과 병행한 한의기반 통합암치료를 통한 전이성 비소세포폐암 환자의 암성 통증 호전 증례보고)

  • Young-min Cho;Jae-ho Yang;Han-eum Joo;So-jeong Park;Ji-hye Park;Hwa-seung Yoo
    • The Journal of Internal Korean Medicine
    • /
    • v.44 no.3
    • /
    • pp.594-601
    • /
    • 2023
  • Objective: To demonstrate an improvement in metastatic cancer pain and a decrease in tumor size in a patient with non-small cell lung cancer. Method: A 53-year-old female patient diagnosed with metastatic non-small cell lung cancer in August 2022 underwent integrative cancer treatment (ICT) for two months to decrease the tumor size and improve back pain from bone metastasis. The patient underwent chemotherapy with ICT. Radiologic outcomes were assessed by chest, abdomen, and pelvis computed tomography based on the Response Evaluation Criteria in Solid Tumors (RECIST) protocol. Clinical outcomes were assessed using National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE), Eastern Cooperative Oncology Group (ECOG), and a numeric rating scale (NRS). Result: During the two months of treatment, the NRS scores for back pain were improved, and the ECOG score improved from grade 2 to 1. The size and metabolic activity of the primary lung tumor decreased and underwent partial remission based on RECIST. No serious side effects of grade 3 or higher were noted on the NCI-CTCAE test. Conclusion: This case suggests that ICT may have a therapeutic effect for cancer pain and a synergetic effect with chemotherapy for metastatic non-small cell lung cancer.

A Man Presenting with Sudden Weakness and Pain of the Right Hand, by Non-Small Cell Lung Cancer with Brain Metastases (비소세포폐암의 뇌전이로 인한 갑작스런 수부 통증 및 마비)

  • Sung, Won Jin;Hong, Bo Young;Kim, Joon Sung;Yoo, Jae Wan;Lim, Seong Hoon
    • Clinical Pain
    • /
    • v.18 no.2
    • /
    • pp.88-91
    • /
    • 2019
  • Unexplained pain and weakness, i.e., without obvious predisposing factors, are often encountered by physiatrists and efforts should be made to determine the cause. A 63-year-old male presented with radiating pain in his right arm and mild weakness of the right hand. An electrodiagnostic examination revealed distal symmetric sensory polyneuropathy in the upper and lower extremities, and denervation potentials in the forearm muscles, which were inconsistent with the cervical spine MRI images and symptoms. A predisposing undiscovered disease was revealed, i.e., squamous cell carcinoma in the lung; brain metastasis affecting the left primary motor cortex was also detected. Therefore, we concluded that the pain and weakness were related to paraneoplastic syndrome and brain metastases of the hand knob. The observed denervation potentials were characterized as trans-synaptic changes in the brain metastasis. This case highlights the importance of unexplainable focal pain and weakness in the increasing prevalence of cancer.